Zevra Therapeutics Stock
Zevra Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Neil F. McFarlane
- Employees
- 61
- Market cap
- $590 M
- IPO
- 16/04/2015
- Web
- zevra.com
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing…
Zevra Therapeutics stock: price history
1D
-3.2%
1W
-12.7%
1M
-15.8%
6M
-6.8%
YTD
+10.9%
1Y
-12.7%
2Y
+17.5%
5Y
+1.7%
10Y
-84.8%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~3% stronger price swings than usual
Ask the agents about Zevra Therapeutics
Analyst assessment of Zevra Therapeutics
PRICE TARGET LOW
US$20.00
CONSENSUS
US$25.75
MEDIAN
US$24.00
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 20/08/2026
Zevra Therapeutics stock metrics
P/E
10.35
P/B
2.7
EV/EBITDA
6.11
RETURN ON EQUITY
4.0%
NET MARGIN
22.1%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.7%
FLOAT SHARES
53,872,372
AVG. DAILY VOLUME (30D)
913,617
Insider transactions (SEC)
McFarlane Neil F.
McFarlane Neil F.
Thompson Rahsaan
Watton Corey Michael
Watton Corey Michael
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.2%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Zevra Therapeutics stock
What does Zevra Therapeutics do?
Zevra Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Neil F. McFarlane, the company employs around 61 people.
The IPO was on 16/04/2015; the stock trades on NASDAQ under the ticker ZVRA.
What do analysts say about Zevra Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 20/08/2026).
The average price target is US$25.75, ranging from US$20.00 to US$35.00, with a median of US$24.00.
This is an external assessment, not a statement by Market Jury.
When does Zevra Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Zevra Therapeutics pay a dividend?
No, Zevra Therapeutics currently does not pay a dividend.
Which stocks are comparable to Zevra Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Zevra Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zevra Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.